View Older Stories View More Recent Stories

Jul 26, 2022 05:53AM MorphoSys AG (MOR) Reports Prelim Q2 Monjuvi US Sales of $23.3M
Jul 26, 2022 05:40AM MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Jul 26, 2022 05:30AM MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Jun 15, 2022 08:42AM MorphoSys (MOR) Announces New License Agreements for Felzartamab and TJ210
Jun 15, 2022 08:41AM I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210
Jun 14, 2022 04:04PM MorphoSys AG (MOR) and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
Jun 14, 2022 04:01PM MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
Jun 13, 2022 04:01PM Pfizer (PFE), MorphoSys (MOR) and Incyte (INCY) Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
Jun 13, 2022 04:01PM Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
Jun 10, 2022 05:36AM MorphoSys AG (MOR) Reports Multiple Analyses of MANIFEST Phase 2 Trial of Pelabresib in Myelofibrosis
Jun 10, 2022 03:15AM MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
May 18, 2022 08:05PM MorphoSys AG Reports Outcome of Annual General Meeting 2022
May 18, 2022 08:05PM MorphoSys AG Reports Outcome of Annual General Meeting 2022
May 12, 2022 10:45AM MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
May 4, 2022 04:01PM MorphoSys AG Reports First Quarter 2022 Financial Results
Apr 28, 2022 04:45PM Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
Mar 22, 2022 04:46PM MorphoSys AG (MOR) and Incyte Announce Swissmedic Temporary Approval of Minjuvi in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
Mar 22, 2022 04:45PM MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
Mar 16, 2022 04:07PM MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Mar 15, 2022 04:40PM National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
Mar 10, 2022 04:35PM Invitation to MorphoSys' Full Year Results 2021 Conference Call on March 17, 2022
Mar 10, 2022 11:30AM MorphoSys AG Reports Non-Cash Impairment Charge of € 231 Million on Goodwill After Consolidation of Research and Discovery Functions; Corresponding Increase of Group Operating Expenses in 2021
Jan 24, 2022 04:20PM MorphoSys ranked Number One in Germany for Female Representation at Leadership Level in European Women on Boards' Gender Equality Index Report
Nov 4, 2021 09:30AM MorphoSys to Present MANIFEST and RE-MIND2 Data from Expanded Hematology-Oncology Portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting
Jan 25, 2021 04:15PM MorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of MOR210/TJ210 in Patients with Advanced Cancer
Jan 25, 2021 04:13PM I-Mab Biopharma (IMAB), MorphoSys (MOR) Report First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer
Jan 25, 2021 04:05PM I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer
Nov 2, 2016 02:34AM MorphoSys and LEO Pharma Enter into Strategic Alliance to Develop Therapeutic Antibodies in Dermatology
Mar 9, 2015 07:00AM Emergent BioSolutions and MorphoSys Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate Cancer
Mar 9, 2015 02:39AM MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study to Evaluate the Novel Oncology Immunotherapeutic MOR209/ES414 for Prostate Cancer
View More Recent Stories View Older Stories